Kinnate Biopharma has been granted a patent for compositions and methods for cancer treatment, involving a RAF inhibitor. The patent includes a method for treating metastatic melanoma with a specific compound, targeting oncogenic BRAF alterations. GlobalData’s report on Kinnate Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Kinnate Biopharma Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Kinnate Biopharma, Targeted cancer therapy was a key innovation area identified from patents. Kinnate Biopharma's grant share as of February 2024 was 11%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for cancer treatment using raf inhibitor

Source: United States Patent and Trademark Office (USPTO). Credit: Kinnate Biopharma Inc

A recently granted patent (Publication Number: US11918587B2) discloses a method for treating cancer in patients with specific genetic alterations. The method involves administering a compound, (S)-N-(3-(2-(((R)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl) pyrrolidine-1-carboxamide, or its pharmaceutically acceptable forms, to patients with metastatic melanoma or non-small cell lung cancer characterized by oncogenic BRAF alterations. For non-small cell lung cancer, the treatment targets specific BRAF mutations such as V600E or V600K, and Class II BRAF mutations.

Furthermore, the patent covers various scenarios for administering the compound, including adjuvant therapy following surgical resection, treatment for patients who have relapsed after prior therapy, those with acquired resistance to previous treatments, and patients who are refractory to therapy. The method allows for oral administration of the compound, providing a convenient treatment option for patients. Overall, the patent outlines a targeted approach for treating cancer based on specific genetic alterations, offering potential benefits for patients with metastatic melanoma or non-small cell lung cancer.

To know more about GlobalData’s detailed insights on Kinnate Biopharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies